GeneDx is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. The company develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
Cyborg Score Rationale
According to 8 analysts, the average rating for WGS stock is Strong Buy. The company reported revenue of $305.45M in 2024 (up 50.79% YoY) with losses of -$52.29M (-70.25% improvement). Strong growth trajectory with improving profitability and analyst conviction.
Top Insights
Revenue grew 50.79% YoY to $305.45M in 2024
Strong Buy consensus with 12-month target of $138.13 (52% upside from current levels)
Partnership with Komodo Health to build the world's most complete longitudinal rare disease dataset
CEO Katherine Stueland named to 2026 TIME100 Health List
Named Competitors
Clinical Exome/Genome Sequencing — Prenatal and hereditary cancer diagnostics
Genetic Testing Services — Clinical genetic testing and data services
Genomic Analysis Platform — Cancer genomic analysis
Recent Developments
(February 2026) Q4 2025 results met guidance and company issued 2026 guidance
(October 2025) Q3 2025 earnings reported with high growth and profitability
(2025) GenomeDx Prenatal whole genome sequencing test launched for fetal anomalies
(2025) Partnership with Komodo Health for longitudinal rare disease dataset
Open the full interactive GeneDx Holdings Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.